SCHEMBL1282885

SCHEMBL1282885

COc1cc(C(=O)Oc2cc[c]cc2)cc(OC)c1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
MAPT P10636 4/20 0.61
POLB P06746 3/20 0.57
ALDH1A1 P00352 2/20 0.57
LMNA P02545 1/20 0.55
MAPK1 P28482 1/20 0.55
TSHR P16473 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
CYP2C9 P11712 1/20 0.51
TUBB4A P04350 3/20 0.50
TUBB P07437 3/20 0.50
TUBA3C P0DPH7 3/20 0.50
TUBA1B P68363 3/20 0.50
TUBA4A P68366 3/20 0.50
TUBB4B P68371 3/20 0.50
TUBB3 Q13509 3/20 0.50
TUBB2A Q13885 3/20 0.50
TUBB8 Q3ZCM7 3/20 0.50
TUBA3E Q6PEY2 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10617966 0.84 MAPT (0.73) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL9970898 0.83 MEN1 (0.81) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL13266325 0.83 MEN1 (0.74) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL15856311 0.81 MEN1 (0.63) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL13963810 0.81 MAPT (0.65) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL9906018 0.81 MEN1 (0.58) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL13266231 0.80 MEN1 (0.66) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL13220873 0.79 ALDH1A1 (0.73) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL5685683 0.77 LMNA (0.62) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL13064968 0.76 MAPT (0.74) MEN1KMT2AMAPTPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088778-A1 AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA, INC. (US) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088778-A1 AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS AGER, S100A4, S100B MEN1 1633/4885KMT2A 4827/4885MAPT 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.